The European Medicines Agency said on Tuesday that it has withdrawn the marketing authorisation for Abbvie's (ABBV.N) hepatitis C drug Exviera at the request of the company.
The regulator said it withdrew the authorisation on Sept. 25. It added that the authorisation holder, AbbVie Deutschland GmbH & Co. KG, had informed the European Commission of its decision to "permanently discontinue the marketing of the product for commercial reasons."
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,